Access Key Required

Please enter the access key provided via email.

Retinal Gene Therapy Collection (6 videos)

A New Vision in Retinal Gene Therapy: From Clinical Trials to Clinical Practice

This collection of content is organized and funded by Novartis Pharma AG.

This collection of content, including a series of six videos, is derived from a recent Novartis sponsored satellite symposium at EURETINA Paris 2019 around innovations in retinal gene therapy. Three leading experts, José Alain Sahel, MD; Bart P. Leroy, MD, PhD; and Mark Pennesi, MD, PhD, offer insights for understanding the patient experience and patient selection, review recent innovations in retinal gene therapy for RPE65 mutations, and discuss implementing retinal gene therapy in clinical practice in relation to treatment with voretigene neparvovec.

In an upcoming issue of Retina Today, there will also be an interactive supplement, so please return for more exciting content from this symposium.


José Alain Sahel, MD

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France

University of Pittsburgh Medical School, Pittsburgh, PA

Bart P. Leroy, MD, PhD

Ghent University and Ghent University Hospital, Ghent, Belgium

Children’s Hospital of Philadelphia, Philadelphia, PA

Mark Pennesi, MD, PhD

Casey Eye Institute, Oregon Health & Science University, Portland OR

This event was organized and funded by Novartis Pharma AG
This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities
The opinions and views expressed in this slide deck are those of the presenters and do not necessarily constitute the opinions or recommendations of Novartis
This presentation was accurate at the time of presentation
Any data about non-Novartis products are based on publicly available information at the time of presentation
Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country
Permissions for all content within have been received from each copyright holder for this presentation
Separate use, adaptation, and/or translation requires application for specific use permissions from each copyright holder
All product names, trademarks and registered trademarks are property of their respective owners

© 2019 Novartis Pharma AG, CH-4002 Basel Switzerland
September 2019 GLOPH/MIS/0197d